Form 4: Krystal Biotech Director Julian Gangolli Granted 5,000 Stock Options

Krystal Biotech, Inc. Director Julian S. Gangolli was granted 5,000 stock options with an exercise price of $137.46, vesting monthly over one year, effective June 30, 2025.

Summary

• Julian S. Gangolli, a Director of Krystal Biotech, Inc. (KRYS), was granted 5,000 stock options.
• The options have an exercise price of $137.46 per share.
• The grant date for these options is June 30, 2025.
• These options will vest in equal monthly tranches over a one-year period following the grant date.
• The options have an expiration date of June 30, 2035.
• Following this transaction, Julian S. Gangolli beneficially owns 5,000 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The grant of stock options to a director aligns their interests with shareholders, incentivizing long-term performance and retention.

Positives

• The grant of stock options to a director aligns management's interests with those of shareholders, incentivizing long-term company performance.
• The options have a 10-year expiration period, providing a long-term incentive for the director.
• The vesting schedule over one year encourages continued commitment and performance from the director.

Future Outlook

The granted stock options will vest in equal monthly tranches over a one-year period following the June 30, 2025 award date.

Industry Context

Granting stock options to directors is a common practice in the biotechnology and pharmaceutical industries, as well as other sectors, to attract, retain, and incentivize key personnel by aligning their financial interests with the company's long-term success and shareholder value creation.

Comparison to Industry Standards

• Granting stock options to directors is a standard practice across publicly traded companies, including those in the biotech sector.
• The specific number of options (5,000) and the exercise price ($137.46) would typically be benchmarked against peer companies of similar market capitalization and stage of development within the biotechnology industry, such as Moderna (MRNA), BioNTech (BNTX), or Regeneron Pharmaceuticals (REGN), to ensure competitive compensation and alignment with performance. Without specific peer compensation data, a direct comparison of the grant's competitiveness is not possible from this document alone.

Corporate Governance

Related Party Transactions

• The grant of stock options to Julian S. Gangolli, a Director of Krystal Biotech, Inc., constitutes a related party transaction as it involves compensation to a member of the company's board.

Stakeholder Impact

• Shareholders: Potentially positive, as the option grant aligns the director's interests with shareholder value creation, incentivizing long-term performance.

Next Steps

• The stock options will begin vesting in equal monthly tranches over a one-year period starting June 30, 2025.

Key Dates

Recommendation

Keywords

Krystal Biotech, KRYS, Stock Options, Director Compensation, SEC Form 4, Insider Transaction, Equity Grant, Julian S. Gangolli, Biotech, Pharmaceuticals